Literature DB >> 29437767

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.

Karolina Woroniecka1,2, Pakawat Chongsathidkiet1,2, Kristen Rhodin1, Hanna Kemeny1, Cosette Dechant1, S Harrison Farber1, Aladine A Elsamadicy1, Xiuyu Cui1, Shohei Koyama3, Christina Jackson4, Landon J Hansen5, Tanner M Johanns6, Luis Sanchez-Perez1, Vidyalakshmi Chandramohan7, Yen-Rei Andrea Yu8, Darell D Bigner7, Amber Giles9, Patrick Healy10, Glenn Dranoff3, Kent J Weinhold11, Gavin P Dunn12, Peter E Fecci13,2.   

Abstract

Purpose: T-cell dysfunction is a hallmark of glioblastoma (GBM). Although anergy and tolerance have been well characterized, T-cell exhaustion remains relatively unexplored. Exhaustion, characterized in part by the upregulation of multiple immune checkpoints, is a known contributor to failures amid immune checkpoint blockade, a strategy that has lacked success thus far in GBM. This study is among the first to examine, and credential as bona fide, exhaustion among T cells infiltrating human and murine GBM.Experimental Design: Tumor-infiltrating and peripheral blood lymphocytes (TILs and PBLs) were isolated from patients with GBM. Levels of exhaustion-associated inhibitory receptors and poststimulation levels of the cytokines IFNγ, TNFα, and IL2 were assessed by flow cytometry. T-cell receptor Vβ chain expansion was also assessed in TILs and PBLs. Similar analysis was extended to TILs isolated from intracranial and subcutaneous immunocompetent murine models of glioma, breast, lung, and melanoma cancers.
Results: Our data reveal that GBM elicits a particularly severe T-cell exhaustion signature among infiltrating T cells characterized by: (1) prominent upregulation of multiple immune checkpoints; (2) stereotyped T-cell transcriptional programs matching classical virus-induced exhaustion; and (3) notable T-cell hyporesponsiveness in tumor-specific T cells. Exhaustion signatures differ predictably with tumor identity, but remain stable across manipulated tumor locations.Conclusions: Distinct cancers possess similarly distinct mechanisms for exhausting T cells. The poor TIL function and severe exhaustion observed in GBM highlight the need to better understand this tumor-imposed mode of T-cell dysfunction in order to formulate effective immunotherapeutic strategies targeting GBM. Clin Cancer Res; 24(17); 4175-86. ©2018 AACRSee related commentary by Jackson and Lim, p. 4059. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29437767      PMCID: PMC6081269          DOI: 10.1158/1078-0432.CCR-17-1846

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  53 in total

1.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Authors:  Ben Youngblood; Kenneth J Oestreich; Sang-Jun Ha; Jaikumar Duraiswamy; Rama S Akondy; Erin E West; Zhengyu Wei; Peiyuan Lu; James W Austin; James L Riley; Jeremy M Boss; Rafi Ahmed
Journal:  Immunity       Date:  2011-09-23       Impact factor: 31.745

2.  Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain.

Authors:  David Zagzag; Konstantin Salnikow; Luis Chiriboga; Herman Yee; Li Lan; M Aktar Ali; Roberto Garcia; Sandra Demaria; Elizabeth W Newcomb
Journal:  Lab Invest       Date:  2005-03       Impact factor: 5.662

3.  Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection.

Authors:  Jill M Angelosanto; Shawn D Blackburn; Alison Crawford; E John Wherry
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

4.  TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

Authors:  Joe-Marc Chauvin; Ornella Pagliano; Julien Fourcade; Zhaojun Sun; Hong Wang; Cindy Sander; John M Kirkwood; Tseng-hui Timothy Chen; Mark Maurer; Alan J Korman; Hassane M Zarour
Journal:  J Clin Invest       Date:  2015-04-13       Impact factor: 14.808

Review 5.  Immune defects observed in patients with primary malignant brain tumors.

Authors:  A R Dix; W H Brooks; T L Roszman; L A Morford
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

6.  Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion.

Authors:  S Huang; S Apasov; M Koshiba; M Sitkovsky
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

7.  Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells.

Authors:  R Martínez-Murillo; A Martínez
Journal:  Histol Histopathol       Date:  2007-12       Impact factor: 2.303

8.  Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.

Authors:  Michael A Paley; Daniela C Kroy; Pamela M Odorizzi; Jonathan B Johnnidis; Douglas V Dolfi; Burton E Barnett; Elizabeth K Bikoff; Elizabeth J Robertson; Georg M Lauer; Steven L Reiner; E John Wherry
Journal:  Science       Date:  2012-11-30       Impact factor: 47.728

9.  BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.

Authors:  Laurent Derré; Jean-Paul Rivals; Camilla Jandus; Sonia Pastor; Donata Rimoldi; Pedro Romero; Olivier Michielin; Daniel Olive; Daniel E Speiser
Journal:  J Clin Invest       Date:  2009-12-28       Impact factor: 14.808

10.  CD39 Expression Identifies Terminally Exhausted CD8+ T Cells.

Authors:  Prakash K Gupta; Jernej Godec; David Wolski; Emily Adland; Kathleen Yates; Kristen E Pauken; Cormac Cosgrove; Carola Ledderose; Wolfgang G Junger; Simon C Robson; E John Wherry; Galit Alter; Philip J R Goulder; Paul Klenerman; Arlene H Sharpe; Georg M Lauer; W Nicholas Haining
Journal:  PLoS Pathog       Date:  2015-10-20       Impact factor: 6.823

View more
  172 in total

1.  Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.

Authors:  Ganesh Rao; Khatri Latha; Martina Ott; Aria Sabbagh; Anantha Marisetty; Xiaoyang Ling; Daniel Zamler; Tiffany A Doucette; Yuhui Yang; Ling-Yuan Kong; Jun Wei; Gregory N Fuller; Fernando Benavides; Adam M Sonabend; James Long; Shulin Li; Michael Curran; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2020-06-18       Impact factor: 12.531

Review 2.  PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?

Authors:  Mustafa Khasraw; David A Reardon; Michael Weller; John H Sampson
Journal:  Clin Cancer Res       Date:  2020-06-11       Impact factor: 12.531

Review 3.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

4.  CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.

Authors:  Joseph A Flores-Toro; Defang Luo; Adithya Gopinath; Matthew R Sarkisian; James J Campbell; Israel F Charo; Rajinder Singh; Thomas J Schall; Meenal Datta; Rakesh K Jain; Duane A Mitchell; Jeffrey K Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-26       Impact factor: 11.205

Review 5.  Replication Stress: An Achilles' Heel of Glioma Cancer Stem-like Cells.

Authors:  Meredith A Morgan; Christine E Canman
Journal:  Cancer Res       Date:  2018-11-29       Impact factor: 12.701

6.  Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.

Authors:  Connor J Liu; Maximilian Schaettler; Dylan T Blaha; Jay A Bowman-Kirigin; Dale K Kobayashi; Alexandra J Livingstone; Diane Bender; Christopher A Miller; David M Kranz; Tanner M Johanns; Gavin P Dunn
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

7.  Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory.

Authors:  Yang Liu; Pakawat Chongsathidkiet; Bridget M Crawford; Ren Odion; Cosette A Dechant; Hanna R Kemeny; Xiuyu Cui; Paolo F Maccarini; Christopher D Lascola; Peter E Fecci; Tuan Vo-Dinh
Journal:  Immunotherapy       Date:  2019-09-18       Impact factor: 4.196

8.  Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity.

Authors:  Katarzyna C Pituch; Markella Zannikou; Liliana Ilut; Ting Xiao; Michael Chastkofsky; Madina Sukhanova; Nicola Bertolino; Daniele Procissi; Christina Amidei; Craig M Horbinski; Karen S Aboody; C David James; Maciej S Lesniak; Irina V Balyasnikova
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

Review 9.  Combination immunotherapy strategies for glioblastoma.

Authors:  Hok Yee Chan; John Choi; Christina Jackson; Michael Lim
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 10.  Pineal Gland Tumor Microenvironment.

Authors:  Joham Choque-Velasquez; Szymon Baluszek; Roberto Colasanti; Sajjad Muhammad; Juha Hernesniemi
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.